Laurion Capital Management LP - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 4 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Laurion Capital Management LP ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,341,036
-51.6%
1,136,471
-42.2%
0.01%
-50.0%
Q2 2023$2,772,408
-22.3%
1,966,247
-17.3%
0.02%
-33.3%
Q1 2023$3,566,910
+28.2%
2,377,9400.0%0.02%
+84.6%
Q4 2022$2,782,190
+3.5%
2,377,9400.0%0.01%
-18.8%
Q3 2022$2,687,000
-29.8%
2,377,940
-1.8%
0.02%
-72.9%
Q2 2022$3,827,000
+34690.9%
2,422,367
+19316.2%
0.06%
Q2 2020$11,00012,4760.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 5,036,720$14,354,0004.77%
BROADWOOD CAPITAL INC 34,005,379$96,915,0004.33%
Prescott General Partners LLC 1,851,851$5,278,0000.17%
Raffles Associates 43,590$124,0000.10%
Laidlaw Wealth Management LLC 123,730$353,0000.09%
DCF Advisers, LLC 74,500$212,0000.08%
Beirne Wealth Consulting Services, LLC 45,000$128,0000.07%
Strategic Wealth Investment Group, LLC 64,232$183,0000.06%
Paradigm, Strategies in Wealth Management, LLC 19,775$56,0000.05%
Fort Sheridan Advisors LLC 47,931$137,0000.05%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders